Evidence map›Paper›PMID 24498455›Full record

ArticlePLoS neglected tropical diseases2014

A cytoplasmic new catalytic subunit of calcineurin in Trypanosoma cruzi and its molecular and functional characterization.

Patricio R Orrego, Héctor Olivares, Esteban M Cordero, Albert Bressan, Mauro Cortez, Hernán Sagua, Ivan Neira, Jorge González, José Franco da Silveira, Nobuko Yoshida and 1 more

Expression of concernAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Cytotoxic Effect ofAdvances in pharmacological and pharmaceutical sciences · 2024
    Article
  4. Article
  5. Article
  6. Interaction With the Extracellular Matrix Triggers Calcium Signaling inFrontiers in cellular and infection microbiology · 2021
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Patricio R OrregoDepartment of Medical Technology, University of Antofagasta, Antofagasta, Chile.
Héctor OlivaresBiomedical Department, University of Antofagasta, Antofagasta, Chile.
Esteban M CorderoDepartment of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.
Albert BressanDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil.
Mauro CortezDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil.
Hernán SaguaDepartment of Medical Technology, University of Antofagasta, Antofagasta, Chile.
Ivan NeiraDepartment of Medical Technology, University of Antofagasta, Antofagasta, Chile.
Jorge GonzálezDepartment of Medical Technology, University of Antofagasta, Antofagasta, Chile.
José Franco da SilveiraDepartment of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.
Nobuko YoshidaDepartment of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.
Jorge E ArayaDepartment of Medical Technology, University of Antofagasta, Antofagasta, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parasitological cure for Chagas disease is considered extremely difficult to achieve because of the lack of effective chemotherapeutic agents against Trypanosoma cruzi at different stages of infection. There are currently only two drugs available. These have several limitations and can produce serious side effects. Thus, new chemotherapeutic targets are much sought after. Among T. cruzi components involved in key processes such as parasite proliferation and host cell invasion, Ca(2+)-dependent molecules play an important role. Calcineurin (CaN) is one such molecule. In this study, we cloned a new isoform of the gene coding for CL strain catalytic subunit CaNA (TcCaNA2) and characterized it molecularly and functionally. There is one copy of the TcCaNA2 gene per haploid genome. It is constitutively transcribed in all T. cruzi developmental forms and is localized predominantly in the cytosol. In the parasite, TcCaNA2 is associated with CaNB. The recombinant protein TcCaNA2 has phosphatase activity that is enhanced by Mn(2+)/Ni(2+). The participation of TcCaNA2 in target cell invasion by metacyclic trypomastigotes was also demonstrated. Metacyclic forms with reduced TcCaNA2 expression following treatment with morpholino antisense oligonucleotides targeted to TcCaNA2 invaded HeLa cells at a lower rate than control parasites treated with morpholino sense oligonucleotides. Similarly, the decreased expression of TcCaNA2 following treatment with antisense morpholino oligonucleotides partially affected the replication of epimastigotes, although to a lesser extent than the decrease in expression following treatment with calcineurin inhibitors. Our findings suggest that the calcineurin activities of TcCaNA2/CaNB and TcCaNA/CaNB, which have distinct cellular localizations (the cytoplasm and the nucleus, respectively), may play a critical role at different stages of T. cruzi development, the former in host cell invasion and the latter in parasite multiplication.

Indexed as

Antigens, ProtozoanCalcineurinCatalytic DomainCell ProliferationCloning, MolecularEndocytosisEnzyme ActivatorsHeLa CellsHumansManganeseMolecular Sequence DataNickelPhosphoric Monoester HydrolasesProtein MultimerizationProtozoan ProteinsSequence Analysis, DNAAntigens, ProtozoanCalcineurincytoplasmic antigen, TrypanosomaEnzyme ActivatorsManganeseNickelPhosphoric Monoester HydrolasesProtozoan Proteins

Identifiers

PMID24498455
PMCPMC3907409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.